Aim: The role of the glutamatergic system in the pathogenesis of obsessive-compulsive disorder (OCD) has been shown by numerous studies. The aim of the present randomized, double-blind, placebo-controlled, 12-week trial was to assess the efficacy and tolerability of amantadine as an adjuvant to fluvoxamine in the treatment of patients with moderate to severe OCD.
Obsessive-compulsive disorder (OCD) is a severe and debilitating neuropsychiatric condition that is characterized by recurrent and intrusive thoughts that the affected individual feels compelled to perform in order to reduce the distress. 1 It affects between 1% and 3% of the general population worldwide and has some sex-related features. 2, 3 Although selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants, and cognitive-behavioral therapy are the firstline medication and treatment of OCD, 4, 5 an estimated 30% of patients are treatment-resistant and complete functional recovery is rare. 6 Therefore, several studies and trials have been done to develop new pharmacotherapeutic agents or modulate different neurotransmitters for treatment of OCD. 7, 8 Glutamate is the major 'excitatory' neurotransmitter of the central nervous system and recent data have pointed to glutamatergic dysfunction in mood and anxiety disorders, OCD, schizophrenia, autism, and attention deficit hyperactivity disorder, as well as neurodegenerative diseases (including Alzheimer's disease, Huntington's disease, and Parkinson's disease). 9 Neuroimaging research studies suggest that as glutamate is the fundamental neurotransmitter of the cortico-striato-thalamo-cortical (CSTC) circuits, CSTC abnormalities play a major role in the pathophysiology of OCD. 10 Additionally, other brain circuits are believed to contribute as well, such as the frontal-striatal circuits, the ventral and dorsal cognitive control circuits, the limbic circuit, the orbitofrontal/basal ganglia brain circuits (caudate), the orbital gyrus, and the dorsal frontoparietal network. [11] [12] [13] [14] [15] Also, abnormalities in serotonergic and dopamine signaling have been assumed to contribute to the etiology of OCD. 16, 17 Lower levels of 5-hydroxytryptamine (serotonin) and increased levels of serotonin metabolite have been seen in OCD patients. The level of the metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) was significantly higher in a small cohort of obsessionals compared with healthy volunteers, possibly reflecting increased brain serotonin turnover. 16 Other pathophysiologic mechanisms include imbalances in neuropeptide neurotransmitters and sex steroids and autoimmune response to Group A streptococcal infections. 15 The role of glutamate dysregulation in the pathophysiology of OCD is supported by numerous studies. 18, 19 Dysregulation of glutamatergic signaling within the cortico-striatal circuitry has been proposed in OCD, with reduced glutamatergic concentrations in the anterior cingulate cortex, combined with overactivity of glutamatergic signaling in the striatum and orbitofrontal cortex. 15 Increase of glutamate in the CSF in OCD patients provides further evidence supporting the neurobiological models of OCD. 20 As a result, glutamate-modulating drugs can be used as treatment in patients with OCD who do not adequately respond to the first-line medication. It is clear that genetic factors play a part in the manifestation of obsessions and compulsions, whether they are clinically significant or not. The role of genetics has been shown in some family and twin studies as well as genome-wide association studies. 21 Recent genetic studies have suggested that polymorphisms in other glutamate-associated genes may contribute to OCD risk, including the SAPAP/DLGAP proteins, the DLGAP1 gene, SAPAP3 knockout, and PTPRD. 22 Several recent studies have demonstrated that glutamatemodulating drugs, as an augmentation agent to serotonin reuptake inhibitors (SRI), can reduce symptoms in OCD patients. 8, 23, 24 Amantadine, an uncompetitive antagonist of the NMDA-type glutamate receptor, 25 has previously been used to treat Alzheimer's and Parkinson's disease, and influenza infection. 26, 27 To the best of our knowledge, only one open-label study has been conducted, in 2014, investigating the effects of amantadine in patients with OCD. 28 Given this evidence, we conducted this double-blind placebo-controlled trial to assess the efficacy and safety of amantadine as an augmentative agent to fluvoxamine in the treatment of moderate to severe OCD.
Methods
Trial setting and design A randomized, double-blind, placebo-controlled trial was conducted over 12 weeks from May 2017 to May 2018 at the outpatient clinic of the Roozbeh Psychiatry Hospital (affiliated with Tehran University of Medical Sciences, Tehran, Iran; Grant 33139). The trial was registered at the Iranian Registry of Clinical Trials (www.irct.ir; registration number: IRCT201705191556N99). The study was conducted in agreement with the Declaration of Helsinki and its subsequent revisions and was approved by the ethics committee of Tehran University of Medical Sciences (IR.TUMS.VCR.REC.1396.2114). Written informed consent was obtained from all eligible participants following complete description of study details. Participants were informed regarding their freedom to withdraw from the trial anytime without any negative effect on their therapy.
Participants
Men and women aged 18-60 years who met the DSM-5 diagnostic criteria for moderate to severe OCD and had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >21 were selected to be in this study. 29, 30 The patients were not allowed to have received any psychotropic medications during the last 6 weeks or to have participated in psychotropic sessions. The patients were excluded if they: had any substance dependence; had an IQ < 70; had any other Axis I mental disorder; had any serious cardiac, renal, or hepatic disease; had received psychotropic medications during the last 6 weeks; were pregnant or breast feeding; or had rising liver transaminases to three times the upper limit of normal or higher. The patients received explanations that they were free to withdraw from the study and to resume standard treatment at any time.
Interventions
The patients were randomized into two parallel groups to receive fluvoxamine (100 mg twice a day) plus amantadine (100 mg daily) or fluvoxamine (100 mg twice a day) plus placebo and were followed for 12 weeks. All patients received 100 mg/day fluvoxamine for 28 days, which was followed by 200 mg/day for the rest of the trial, regardless of their treatment groups.
Outcomes Y-BOCS was used for assessment of patients. It has been used widely for rating the severity of OCD in several clinical trials in Iran. [31] [32] [33] The patients were evaluated at baseline and at Weeks 4, 10, and 12.
The main outcome of this study was measurement of difference in Y-BOCS total score between the two groups in this study from baseline to the end. Measurement of differences in the Y-BOCS Obsession and Compulsion subscales between the two study groups from baseline to the end was defined as the secondary outcome. Other secondary outcomes included difference in partial response rate (defined as ≥25% reduction in Y-BOCS score), complete response rate (defined as ≥35% reduction in Y-BOCS score), and remission rates (score ≤ 16) between the two groups. 34 All measurement was done by the same raters who were blind to the intervention. Adverse effects were recorded over the trial. In each visit, the patients were asked about occurrence of adverse effects by using a structural checklist. [35] [36] [37] Two well-trained and experienced raters were responsible for all assessments with inter-rater reliability of ≥90% while they were blinded to the treatment allocation (based on tape review method).
Sample size
Assuming a difference of 4 points on Y-BOCS between the amantadine and the placebo groups, a standard deviation of 5, two-sided significance level of 0.05, and a standard power of 95%, a sample size of 84 (each group 42) was calculated. With prediction of 80% rate of attrition, a total number of 100 patients (each group 50) was needed.
Randomization, allocation concealment, and blinding
The random permuted block method (allocation ratio 1:1, blocks of four) was used for randomization of patients. Treatment allocation was concealed from patients and physicians who rated patients by using successively numbered, opaque, sealed envelopes. Separate individuals were responsible for randomization and rating patients. Amantadine and placebo were distributed in identical shapes and colors. The patients, physicians who evaluated them and prescribed medications, and the statistician were all blind to allocation.
Safety
The participants received thorough explanations that they were free to withdraw from this trial and return to their standard treatment. The patients were asked to inform the physician of any unexpected symptoms or complaints during the trial. Physical examination was performed for all patients and their vital signs were recorded at the screening session. They were asked about adverse events through open questions followed by a complete adverse event checklist (a 25-item checklist). Necessary lab tests, such as complete blood count, aspartate aminotransferase, and alanine aminotransferase, were done each month.
Statistical analysis SPSS 25 (IBM, Armonk, NY, USA) was used to carry out data analysis. The categorical variable was presented as the number of patients and as a percentage. Continuous variables were reported as mean AE SD unless stated otherwise and mean (95% confidence interval [CI]) was used to report mean difference (MD). Two-factor repeatedmeasure analysis of variance (ANOVA) was used to assess the effect of time and time-group (treatment) interactions. Results of GreenhouseGeisser correction were reported whenever Mauchly's test of sphericity was significant. To compare score changes from baseline between the two study groups, the t-test was performed. Categorical variables were compared using Fisher's exact test or the χ 2 -test. A P-value < 0.05 was considered significant.
Result Participants
A total of 140 patients were primarily screened for desirability criteria. One hundred and six patients were randomly allocated to two groups. Fifty-three received fluvoxamine plus amantadine and 53 received fluvoxamine plus placebo. Finally 100 patients (51 patients in the fluvoxamine plus amantadine group and 49 patients in the fluvoxamine plus placebo group) completed the trial (Fig. 1) . Table 1 shows that the baseline characteristics of treatment in the two groups were not significantly different.
Y-BOCS total score
The Y-BOCS total score did not differ between the two groups signif f. = 1.50, P-value = 0.03) by using repeated-measure ANOVA (Fig. 2) . By the end of the trial, 22 amantadine group patients and 14 placebo group participants had achieved remission (P-value = 0.12). Also, 43 amantadine group patients compared to 22 placebo group participants met the criteria for complete or partial response, which was significant (P-value < 0.001). The independent sample t-test revealed significant difference at each point of the trial between the two groups ( Table 2) .
Y-BOCS Obsession score
The Y-BOCS Obsession score did not differ between the two groups significantly at baseline (MD [95%CI] = 0.45 [−0.80, 1.12], t = 1.31, P-value = 0.19). A significance effect was observed for Time × Week interaction, Greenhouse-Geisser corrected (F = 5.67, d.f. = 1.48, P-value < 0.01) by using repeated measure ANOVA (Fig. 3) . The independent sample t-test revealed significant differences at each point of the trial between the two groups ( Table 2) . (Fig. 4) . The independent sample t-test revealed insignificant differences at each point of the trial between the two groups ( Table 2) .
Adverse effect Adverse effects were recorded over the study. There was no serious adverse effect in the two groups. Frequency of side-effects did not differ between the two groups (Table 3) . 
Discussion
We conducted a randomized, double-blind, placebo-controlled trial to evaluate the effectiveness of amantadine as an adjuvant to fluvoxamine and followed 100 OCD patients over a 12-week period of therapy. The results provide evidence that amantadine caused a reduction in Y-BOCS total and Obsession subscale scores of patients in the amantadine group, compared to the control group, during the course of this trial. There was no significant difference in side-effects between the placebo and the amantadine group and, therefore, we conclude that amantadine is an effective adjuvant to fluvoxamine in reducing OCD symptoms.
Glutamate is a major excitatory neurotransmitter and is involved in almost all circuits in the central nervous sytem. 38 Several investigations have suggested that synaptic dysfunction of the glutamatergic system contributes to pathogenesis of OCD. 8, 18 Glial cells, mostly astrocytes, have some transporters and antiporters that control the amount of glutamate in synaptic clefts to prevent its excitotoxicity effects. 18, 39, 40 A recent study has shown association between structural or functional variants of these transporters, due to single nucleotide polymorphisms, and obsessive-compulsive disorder. 41 Chakrabarty et al. showed that CSF glutamate levels were significantly raised in OCD patients compared to normal controls, and that the difference was unrelated to age or sex of the subjects. 42 CSTC dysregulation and hyperactivity of the orbitofrontal cortex and the ventromedial striatum are correlated with OCD. 13, 14 Animal studies also support the role of the CSTC pathway in the pathophysiology of OCD. In a scientific study, after 5 days of stimulation of orbitofrontal cortex-ventromedial striatum areas, mice showed progressive grooming, which is a mouse behavior related to OCD. 43 Therefore, it has been suggested that glutamate-modulating agents be used as a treatment in OCD patients, especially those who do not adequately respond to the first-line medication.
According to the fact that glutamate dysregulation may play a possible role in the pathogenesis of OCD, research has been done on glutamate-modulators. In a double-blind, randomized, and placebocontrolled trial, Haghighi et al. showed that memantine (5-10 mg/day) combination therapy with clomipramine or SSRI significantly had positive influence on patients suffering from refractory OCD. 44 A randomized, double-blind, and placebo-controlled trial by Emamzadehfard et al. assessed the effect of riluzole augmentation on 50 OCD patients who had not responded to SRI treatment. Significant improvement of symptoms was observed at the end of 10 weeks. 23 Paydary et al. revealed that in spite of the fact that N-acetylcysteine augmentation therapy was not effective in reducing the Y-BOCS Compulsion subscale score, it significantly reduced the Obsession subscale and total score. 45 Rodriguez et al. reported that ketamine infusion, a non-competitive NMDA glutamate receptor antagonist, without the use of an SRI, can cause reduction in OCD symptoms. 46 Possible effect of lamotrigine, 47 topiramate, 48 L-carnosine, 49 and 7 in reduction of OCD symptoms has been shown in similar studies.
Amantadine is an uncompetitive antagonist of NMDA-type glutamate receptor that has a neuroprotective potential. Indirectly, by blocking NMDAR, it also exerts a dopamine-enhancing activity. 25, 47 Formerly, it was assumed that amantadine enhances dopamine activity by facilitating presynaptic dopamine release and blocking dopamine reuptake post-synaptically. 50 Therefore, it acts on both the glutamatergic and the monoaminergic system. Amantadine inhibits the openchannel times of NMDA receptors, despite fast unbinding kinetics, and increases the occupancy of the channel's closed states with a mechanism termed 'trapping channel block. ' 51 By binding to the NMDA receptors and blocking glutamate access to the cells, amantadine exerts a neuroprotective effect on the excitotoxic damage induced by glutamate. 25, 50 Patients with OCD show a disruption of functioning in the frontostriatal circuit and alterations in dopamine signaling, which is mostly reduced binding to D 2 receptors in the striatum. A reduction in binding potential to D 2 receptors may result from increased striatal dopamine levels or altered availability of D 2 receptors. 52 The administration of memantine (10 mg/kg, i.p.) and amantadine (30 mg/kg, i.p.) inhibited marble-burying behavior in mice, which is considered to be an animal model of OCD. 53 Nevertheless, the exact mechanism of action of amantadine is not clearly understood and future studies are needed to explicate the way amantadine can improve symptoms of OCD.
Amantadine (1-adamantanamine hydrochloride) is an antiviral drug that was formerly used for prophylaxis and treatment of influenza A. 26 It is also used to improve alertness and arousal in posttraumatic brain injury in children. 54 NMDA receptor antagonists, such as amantadine and memantine, have been shown to have several neuroprotective effects. 25 Amantadine can improve executive dysfunction in patients with Alzheimer's dementia 27 and Huntington's disease, 55 the early stages of Parkinson's. 27 In addition, amantadine has been used to treat fatigue and improve attention and other cognitive functions in multiple sclerosis. 56 Amantadine can also be effective in treatment of autistic disorder in children, 57 and in reducing the symptoms of attention deficit hyperactivity disorder in children. 58 Pasquini et al. reported that a treatment-resistant patient with OCD responded to amantadine (200 mg/day) added to clomipramine (225 mg/day). 59 In an open-label study of amantadine in eight OCD patients who had failed one SSRI trial, 28 significant reductions in total Y-BOCS (28 AE 4.5 vs 18.8 AE 8.8; P < 0.01; d.f. = 7; t = 2.36), Y-BOCS Compulsion subscale (15.3 AE 3.2 vs 10.6 AE 4.7; P < 0.02; d.f. = 7; t = 2.36), and Y-BOCS Obsession subscale (12.7 AE 3.3 vs 8.1 AE 5; P < 0.05; d.f. = 7; t = 2.36) scores were obtained at endpoint and the anxiety and depression levels remained unaltered.
This study has some limitations that need to be addressed as they may impair interpretation of the findings. First, due to ethical considerations, there was no placebo-only group in this study. As a result, it was not possible to determine the therapeutic effects of amantadine exclusively. Second, as the participants were not treatment-refractory, the results might not extend to treatment-refractory patients. Also, patients suffering from other concomitant psychiatric disorders were excluded. Third, a long-term follow-up period is indispensable considering that OCD has a high chance of multiple relapses during the course of the disease. Fourth, the effects of higher doses of amantadine on OCD symptoms were not determined during the course of our study. Lastly, subgroup analysis to compare the effects of treatments based on clinical characteristics of patients was not performed in this trial and weekly assessments of Y-BOCS scores could help to determine time-to-effect more accurately.
Conclusion
In this study, the efficacy of amantadine was evaluated as an augmentative medication among patients with moderate to severe OCD. Amantadine was administered with a dosage of 100 mg daily with no severe side-effects. This double-blind clinical trial shows the potential benefits of amantadine in combination with fluvoxamine, a first-line drug. However, before confirming routine usage of amantadine in practice, replication of these findings is required by further studies with longer durations of therapy, and in combination with different subtypes of serotonin receptor inhibitors.
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